



Release No 69

31 May 2002

## **Lundbeck and Mochida enter into agreement on the development and sale of Cipralex® in Japan**

H. Lundbeck A/S and Mochida Pharmaceutical Co., Ltd have signed a semi-exclusive licence agreement on the development, registration, sale and marketing of Cipralex® (escitalopram) on the Japanese market.

"I am very pleased that Lundbeck has entered into an agreement that within some years will introduce Cipralex® on the Japanese market – giving also Japanese patients access to the best and the only second generation drug available for the treatment of depression and panic disorders", says Lundbeck's President & CEO, Erik Sprunk-Jansen

Lundbeck's collaboration with another Japanese pharmaceutical company, Mitsui Pharmaceuticals, is thus no longer in effect.

The content of this release will have no influence on the Lundbeck Group's result for 2002. The company still expects an increase in turnover of approx. 20% compared to 2001, while the operating profit still is expected to increase by 20% compared to 2001.

For further information please contact Hans Henrik Munch-Jensen, CFO, tel +45 36 30 15 11, ext. 2660 or Steen Juul Jensen, Director of Corporate Communication & Investor Relations, tel +45 36 30 13 11, ext. 3006.

---

Mochida Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company engaged in the research and development, manufacturing and sale of pharmaceuticals, medical equipment and healthcare products. The company was founded in 1913 and listed on the first section of the Tokyo Stock Exchange in 1975. In fiscal year 2001 the company generated revenues of JPY 63.3 billion and as of 31 March 2002 the number of employees was 1,728.

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2001, the Company's revenue was DKK 7.7 billion and the number of employees approx. 4,000